The significant upfront payment and substantial milestone potential provide non-dilutive funding for C4T's pipeline development. The partnership with Roche validates C4T's technology platform. The deal structure with Roche's right to terminate for convenience introduces some execution risk.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 9 $2.83entry
- T+1 · 7mo ago −10.42%α −10.36% · $2.54
- T+5 · 7mo ago +2.47%α −0.71% · $2.90
- T+20 · 6mo ago +3.53%α −4.03% · $2.93
- T+60 · 4mo ago +46.29%α +35.51% · $4.14
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
C4 Therapeutics entered a research collaboration and license agreement with Roche to develop degrader-antibody conjugates (DACs) for two undisclosed oncology targets, with an option for a third. The deal includes a $20 million upfront payment and over $1 billion in potential milestone payments plus royalties. This partnership leverages C4T's TORPEDO platform and Roche's ADC expertise.
Key Financial Metrics
Key Facts
- C4 Therapeutics and Roche entered a collaboration agreement for degrader-antibody conjugates (DACs)
- Roche will develop, manufacture, and commercialize DACs directed to two initial undisclosed oncology targets
- C4T receives $20 million upfront payment
- C4T is eligible to receive over $1.0 billion in aggregate milestone payments
- C4T will receive tiered royalties on net sales ranging from mid-single digit to low-double digit percent
- Roche has the right to terminate the agreement for convenience with 90 days notice
Financial Impact
$20 million upfront payment and over $1.0 billion in potential milestone payments
Risk Factors
- Roche can terminate the agreement for convenience with 90 days notice
- The success of the collaboration depends on achieving specified research and development milestones
- The upfront payment is modest compared to the potential milestone payments
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-024336 |
| Document: aprilcorporatedeck_final.htm | 0001628280-26-024336 |
| Document: cccc-20260409xexx991.htm | 0001628280-26-024336 |
| Document: 0001628280-26-024336-index-headers.html | 0001628280-26-024336 |
| Document: 0001628280-26-024336-index.html | 0001628280-26-024336 |
| Document: 0001628280-26-024336.txt | 0001628280-26-024336 |
Track record
19 reports on CCCC
4 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +46.29% at T+60 after the Apr 9, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $2.71 Now $2.65 −2.03% settles Nov 23
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $2.76 Now $2.65 −3.99% settles Nov 20
- Nov 6, 202610d ago Institutional Cluster Neutral 2/10 Entry $3.10 to $2.76 Now $2.65 −14.52% ▼ −10.97% −13.56% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $2.95 to $2.77 Now $2.65 −10.17% ▼ −6.10% −9.39% vs SPY
- Sep 25, 20267w ago 8-K Neutral 4/10 Entry $2.98 to $2.95 Now $2.65 −11.07% ▼ −1.01% −0.79% vs SPY
- Sep 25, 20267w ago Press Release Neutral 4/10 Entry $2.98 to $2.95 Now $2.65 −11.07% ▼ −1.01% −0.79% vs SPY
- Aug 14, 202613w ago 144 Neutral 3/10 Entry $4.27 to $4.10 Now $2.65 −37.87% ▼ −3.87% −2.68% vs SPY
- Aug 14, 202613w ago Institutional Cluster Bullish 6/10 Entry $4.27 to $4.10 Now $2.65 −37.87% ▼ −3.87% −2.68% vs SPY
- Aug 11, 202613w ago 8-K Neutral 5/10 Entry $3.87 to $4.18 Now $2.65 −31.52% ▲ +8.01% +8.41% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers